Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
48pct
9d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2015 · second_quarter · Alcohol and Drug Abuse
Dextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (re-introduction of Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644 in the 113th Congress, all sections).
Client expense: $250,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2015 · first_quarter · Alcohol and Drug Abuse
Dextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (re-introduction of Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644 in the 113th Congress, all sections).
Client expense: $140,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Alcohol and Drug Abuse
Dextromethorphan S.644-Preventing Abuse of Cough Treatments Act H.R.3969-Preventing Abuse of Cough Treatments Act Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2014 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug user fees. Monitor legislative and administrative action related to Medicare's 2011 guidance on servicing hospital equipment, including medical imaging equipment. Monitor legislative and administrative action related to drug safety and drug counterfeiting (track and trace). Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to the 340B Drug Pricing Program. Monitor legislative and administrative action related to federal preemption for prescription drugs. Monitor legislative and administrative action related to point-of-care instruments. Monitor legislative and administrative action related to streamlined pathways to market for breakthrough technologies. Monitor legislative and administrative action related to access to medical supplies. Monitor legislative and administration action related to Tropical Disease Priority Review Voucher Program. Monitor activities related to House Energy and Commerce Committees 21st Century Cures Initiative. H.R. 1150, Preservation of Antibiotics for Medical Treatment Act of 2013. Title II and general provisions in the bill. H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013. H.R. 4302, Protecting Access to Medicare Act. Provisions related to imaging and Sec. 213. S. 1256, Preventing Antibiotic Resistance Act of 2013. S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013. H.R. 4771, Designer Anabolic Steroid Control Act of 2014. S. 2012, Designer Anabolic Steroid Control Act of 2014. Monitor the implementation of the Patient Protection and Affordable Care Act, P.L. 111-148. H.R. 1295, Medical Device Tax Elimination Act. S. 2917, Adding Ebola to the FDA Priority Review Voucher Program Act. H.R. 3969, Preventing Abuse of Cough Treatments Act of 2014 or the PACT Act. S. 644, Preventing Abuse of Cough Treatments Act of 2013 or the PACT Act.
Client expense: $1,240,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2014 · fourth_quarter · Pharmacy
Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act; HR 4895/S.2902, Microbead-Free Waters Act of 2014; HR 5613, Protecting Our Kids' Medicine Act of 2014
Client expense: $1,242,788 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2014 · fourth_quarter · Alcohol and Drug Abuse
Dextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644, all sections).
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Consumer Issues/Safety/Products
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
Client expense: $1,400,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2014 · third_quarter · Alcohol and Drug Abuse
DextromethorphanDextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644, all sections).
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan including S.644 and H.R.3969 the PACT Act - Preventing Abuse of Cough Treatments Act of 2013.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2014 · fourth_quarter · Alcohol and Drug Abuse
S. 644 and HR 3969- Preventing Abuse of Cough Treatments Act of 2014. Availability of allergy medicine with Pseudoephedrine
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Alcohol and Drug Abuse
Dextromethorphan S.644-Preventing Abuse of Cough Treatments Act H.R.3969-Preventing Abuse of Cough Treatments Act Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
2014 · third_quarter · Pharmacy
Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act; HR 4895/S.2902, Microbead-Free Waters Act of 2014; HR 5613, Protecting Our Kids' Medicine Act of 2014
Client expense: $1,060,676 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2014 · third_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Consumer Issues/Safety/Products
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
Client expense: $1,350,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
2014 · third_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan including S.644 and H.R.3969 the PACT Act - Preventing Abuse of Cough Treatments Act of 2013.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2014 · third_quarter · Alcohol and Drug Abuse
DextromethorphanDextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644, all sections).
Client expense: $220,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Alcohol and Drug Abuse
S. 644 and HR 3969- Preventing Abuse of Cough Treatments Act of 2014. Availability of allergy medicine with Pseudoephedrine
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Alcohol and Drug Abuse
Dextromethorphan S.644-Preventing Abuse of Cough Treatments Act H.R.3969-Preventing Abuse of Cough Treatments Act Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Client expense: Not reported · Firm income: $40,000
2014 · second_quarter · Pharmacy
Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act; HR 4895, Microbead-Free Waters Act of 2014
Client expense: $1,571,606 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2014 · second_quarter · Consumer Issues/Safety/Products
- Issues related to dextromethorphan. - Issues related to pseudoephedrine. - Issues related to the regulation of cosmetic products. - HR 1385, "Safe Cosmetics and Personal Care Products Act of 2013", regarding all provisions.- S 644/ HR 3969, "Preventing Abuse of Cough Treatments Act of 2013", regarding all provisions.
Client expense: $1,060,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act. H.R. 4502: Stop Meth Labs and Enhance Patient Access Act of 2014.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Alcohol and Drug Abuse
DextromethorphanDextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, H.R. 3969/S. 644, all sections).
Client expense: $230,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan including S.644 and H. R.3969 the PACT Act - Preventing Abuse of Cough Treatments Act of 2013.
Client expense: Not reported · Firm income: $50,000
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · second_quarter · Alcohol and Drug Abuse
S. 644 and HR 3969- Preventing Abuse of Cough Treatments Act of 2014. Availability of allergy medicine with Pseudoephedrine
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Alcohol and Drug Abuse
Dextromethorphan S.644-Preventing Abuse of Cough Treatments Act H.R.3969-Preventing Abuse of Cough Treatments Act Legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications
Client expense: Not reported · Firm income: $40,000
2014 · first_quarter · Health Issues
H.R. 4302, Protecting Access to Medicare Act of 2014 (P.L. 113-93); H.R. 2575, Save American Workers Act; H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013; H.R. 3969/S. 644, PACT Act; H.R. 4069, Ensuring Patient Access and Effective Drug Enforcement; Implementation issues related to the Patient Protection and Affordable Care Act (P.L. 111-148).
Client expense: $180,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · first_quarter · Alcohol and Drug Abuse
Dextromethorphan abuse - HR 3969, PACT Act; S 644, PACT Act.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan including S.644 and H. R.3969 the PACT Act - Preventing Abuse of Cough Treatments Act of 2013.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Alcohol and Drug Abuse
S. 644 and HR 3969- Preventing Abuse of Cough Treatments Act of 2014. Availability of allergy medicine with Pseudoephedrine
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
Dextromethorphan Abuse Reduction; Regulation of OTC drugs, devices and cosmetics; S.644, Preventing Abuse of Cough Treatments Act of 2013; HR 3969, Preventing Abuse of Cough Treatments Act of 2013; S.2141, The Sunscreen Innovation Act; HR 4250, The Sunscreen Innovation Act
Client expense: $1,094,205 · Firm income: Not reported
Government targets: Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Commodity Futures Trading Commission (CFTC), Consumer Product Safety Commission (CPSC), Energy, Dept of, Environmental Protection Agency (EPA), Executive Office of the President (EOP), Federal Communications Commission (FCC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Securities & Exchange Commission (SEC), State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2014 · first_quarter · Health Issues
Education and outreach regarding S. 644, H.R. 3969: PACT Act, which restricts access to cough medicine by minors and limits bulk sales of raw, unfinished Dextromethorphan. H.R. 2835: Restoring Access to Medication Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| IA |
| Doris O. Matsui | Democratic | CA |
| H. Morgan Griffith | Republican | VA |
| James B. Renacci | Republican | OH |
| Marsha Blackburn | Republican | TN |
| Michael C. Burgess | Republican | TX |
| Pete Olson | Republican | TX |
| Peter A. DeFazio | Democratic | OR |
| Renee L. Ellmers | Republican | NC |
| Suzan K. DelBene | Democratic | WA |
| Tim Ryan | Democratic | OH |
| Zoe Lofgren | Democratic | CA |
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE